YOUR SEARCH FOR Text 15 RESULTS
11 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… amplification/Cyclin E overexpression: Phase 1 INCB161734 (KRASG12D) Advanced metastatic …
12 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… amplification/Cyclin E overexpression: Phase 1 INCB161734 (KRASG12D) Advanced metastatic solid …
13 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Amplification/ Overexpression of CCNE1: Phase 1 INCB161734 (KRASG12D) Advanced metastatic …
14 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Amplification/ Overexpression of CCNE1: Phase 1 INCB161734 (KRASG12D) Advanced metastatic …
15 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… amplification/Cyclin E overexpression: Phase 1 INCB161734 (KRASG12D) Advanced metastatic …
A New Frontier
in Hematology
Incyte proudly adds VGA039 and the
VIVID study to its hematology portfolio.